Introduction
Substances and New Organisms (HSNO) Act (1996) . The EPA can regulate on the 33 basis that an organism that has been treated with dsRNA is a new organism, or 34 instead categorize RNA as a chemical that could be a hazardous substance. 35 RNA is not now and unlikely ever to be listed as a hazardous substance. This is 36 deduced from the observation that none of the terms RNA, dsRNA, ribonucleic acid, 37 or siRNA return anything in a search of the EPA's databases: "Approved hazardous 38 substances with controls", "Chemical Classification and Information Database", or 39 "New Zealand Inventory of Chemicals." Moreover, the Ministry of Primary Industries 40 places RNA in the "Neglible Risk Register" (MPI 2018) . 41
In which case if dsRNA-treated organisms are to be regulated at all, they must be 42 under the country's biosecurity laws * directed at pathogens and pests, or as new 43 organisms by the HSNO Act. A new organism may be in a species or sub-species new 44 to New Zealand and/or be a genetically modified organism of any species (full 45 definition in Supplemental Material). Here I analyze the routine case where an 46 organism that is not new (or considered to be a biosecurity threat) is treated with 47 dsRNA, and whether that treatment results in the organism being a new organism 48 under the HSNO Act, by creating a genetically modified organism. 49
The HSNO Act says that a "genetically modified organism means, unless expressly 50 provided otherwise by regulations, any organism in which any of the genes or other 51 genetic material-(a) have been modified by in vitro techniques; or (b) are inherited 52 or otherwise derived, through any number of replications, from any genes or other 53 genetic material which has been modified by in vitro techniques" (1996) . 54
New Zealand is harmonized to the Cartagena Protocol on Biosafety (the Protocol) 55 (CBD) through its HSNO Act. The Protocol is an international treaty on the 56 transboundary movement of products of modern biotechnology, including living 57 genetically modified organisms. The Protocol does not apply to food and 58 pharmaceutical products that are unable to survive in the environment. The 59
Protocol definition of a living modified organism is "any living organism that 60 possesses a novel combination of genetic material obtained through the use of 61 modern biotechnology." The Protocol definition of modern biotechnology is "the 62 application of: a. In vitro nucleic acid techniques, including recombinant 63 deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or 64 organelles, or b. Fusion of cells beyond the taxonomic family, that overcome natural 65 physiological reproductive or recombination barriers and that are not techniques 66 used in traditional breeding and selection." 67
Binding international agreements such as the Cartagena Protocol create a network 68 of countries with shared obligations. Domestic legislation or sui generis authority is 69 required by each country to meet its obligations. As a result, legal frameworks arise 70 that tend to have similarities, and challenges to them in one member country are 71 frequently encountered also by others (Kershen 2015 ). An example is the use of 72 techniques referred to as gene editing. New Zealand was the first country in the 73 world to establish its legal view on gene editing techniques (Kershen 2015) . These 74 questions were and are discussed in many countries, but notably all countries that 75 are bound to the Protocol and its language will be affected by the decisions member 76 countries make. The Committee's Decision in context is about the use of exo-dsRNA for the purpose 134 of causing RNAi (Box 1). As the nature and source of the dsRNA applied as exo-135 siRNA is undefined by the EPA in its Decision, I will often use the term exo-dsRNA as 136 a more generic description than exo-siRNA in this analysis. 137
Analysis of the Decision is made more complicated because the EPA Decision-138
Making Committee described the application in various, and significantly different, 139 ways (Table S1 ) and different to the descriptions provided by either the applicant 140 (Trought 2018) Hypothetical uses on post-harvest or retail foods include for the purposes of 171 delaying ripening or spoilage. For example, genetically modified tomatoes were 172 engineered to produce dsRNA to silence the expression of 1-aminopropane-1-173 carboxylate synthase, the rate-limiting enzyme in the production of the ripening 174 hormone ethylene. The expression of dsRNA was controlled by a promoter that was 175 mainly active late in development so as to not interfere with the production of 176 ethylene at other stages of fruit development (Gupta et al. 2013 ). The effects of 177 silencing at the wrong time could alternatively be avoided by spraying exo-dsRNA 178 on harvested but unripe tomatoes. Other approaches are to use topically applied 179 exo-dsRNA to silence genes that are receptors of ethylene (Deikman et al. 2017) . 180
In these cases the primary concern would be the quality and purity of the dsRNA 181 active ingredient. As discussed in more detail later in this analysis, the EPA Decision 182 was agnostic to methods of preparing the dsRNA, or the size of the RNA molecules 183 that might be used. 
Kinds of RNA molecules and treatments 205
The Committee did not address the physical description of the dsRNA in the 206 approved treatments. The applicant sought permission to use "synthetic" dsRNA, 207
restricted as well to those that would cause a temporary effect on the "activity of the 208 complementary RNA" (Trought 2018 and when compared to an untreated plant. Several embodiments include progeny 265 seed or propagatable plant part of such plants, and commodity products produced 266 from such plants" (Huang et al. 2018) . 267
The maker of the dsRNA would apparently own an organism because it was exposed 268 to the dsRNA, potentially including entire fields of conventional crops or long-lived 269 trees and their seeds that have never been modified by insertion of DNA. The nomenclature should be used as an indicative guide to biogenesis of the dsRNA, but not the activity of the active form. This is because regardless of their source, dsRNAs share the same pathways in the cell (Ghildiyal & Zamore 2009 ). "For example, siRNA is able to mimic microRNA (miRNA) to inhibit translation or elicit the degradation of [messenger RNAs] with partial sequence complementarity" (Zhou et al. 2014 ).
All three active forms derive from longer dsRNAs. Cytoplasmic Dicer converts the longer form of siRNA and miRNA into the active form of about 21-23 nucleotides. Argonaute proteins bind to the RNA and carry out the regulatory functions (Carthew & Sontheimer 2009 ). Drosha (or Dcl1) acts in the nucleus to process pri-miRNA into pre-miRNA, which after transport to the cytoplasm is further processed to miRNA by Dicer (Kim et al. 2009 ).
Once associated with the Argonaute proteins, one strand of the dsRNA molecule is degraded and the other serves to guide the protein complex to its target. Some eukaryotic species have Argonaute proteins that can bind either miRNA or siRNA, and some that specialize in one or the other, while other species have Argonaute proteins that distinguish between miRNA and siRNA based on the structural features of the dsRNA. While endo-siRNA, miRNA and piRNA may be born differently, they are not reliably distinguished by the silencing biochemistry. Both miRNA and piRNA arise from transcription of genomic DNA. Although this can also be true for siRNA, such as from transgenes or transposons (endo-siRNAs), the term is also often reserved for exosiRNAs even if they have a hairpin structure. In general, miRNAs are not transcribed from the protein coding region of a gene and may have more mismatches with their targets. The converse is true for siRNAs. Thus, miRNA, piRNA and endo-siRNA all first appear in the nucleus and exo-siRNA does not (Carthew & Sontheimer 2009 ).
It is not possible to confidently extrapolate the outcome of exposure to exo-siRNA based on similarity of nomenclature to endo-siRNA. Because of differences between organisms and differentiated cell types, generalizations based even on the structure of the dsRNA molecule often fail.
Exo-dsRNA is not confined to the cytoplasm

275
The Committee understood that exo-siRNA remains "solely as RNA molecules in the 276 cell cytoplasm outside the nucleus" (EPA 2018a), consistent with advice received 277 from staff (paragraph 2.9 of Ref EPA 2018b). Physical isolation of the genes and 278 other genetic material in the nucleus would be a biological barrier to inheritance of 279 exo-dsRNA that was confined to the cytoplasm (Fig. 1) . 280
However, no such barrier can be relied upon to keep dsRNA out of the nucleus. Among potential barriers to inheritance is that exo-siRNAs will not be reverse 318 transcribed (Fig. 1) . Unfortunately, neither the Decision nor Staff Advice provided 319 references or analysis for the definitive existence of such a barrier. 320
Reverse transcriptase has the ability to synthesize a DNA molecule using an RNA 321 molecule as a co-factor (template), similar to how DNA itself replicates using a DNA 322 strand as a co-factor in DNA replication. Once a DNA strand has been synthesized by 323 reverse transcriptase, that strand can serve as a co-factor in the synthesis of a 324 complementary strand to produce a double-stranded DNA molecule. 
2018). 332
Reverse transcriptase requires a primer to initiate synthesis. A primer is another 333 nucleic acid polymer, usually RNA (such as a dsRNA molecule called a tRNA), that 334 provides a 3´OH group for strand extension. The primer may come from the 335 secondary structure (eg a hairpin structure), as is common in precursors of siRNA. 336
Alternatively, the primer is a second molecule that binds to the template strand. The 337 primer gives the reverse transcriptase reaction specificity because it binds by 338 complementarity to a target sequence. At least in the laboratory, it is possible for a 339 reverse transcriptase reaction to proceed without the addition of any particular 340 primer molecule because there are sufficient numbers of small RNA molecules 341 naturally present in the cytoplasm to serve this purpose (Frech & Peterhans 1994) . 342
It is uncertain whether all exo-dsRNA molecules could be substrates for reverse 343 transcriptase, but it is unlikely that none could be. RNA from viruses can be 344 captured by reverse transcriptase for conversion into DNA molecules and 345 integration into chromosomal DNA, as well as by Dicer for production of siRNA 346 (Goic et al. 2013 In both people and plants methylation tends to occur more in genes with naturally 407 lower numbers of C residues, presumably because of historical deleterious 408 transition mutations at these loci (Zilberman 2017 The limiting mechanisms are also not assurances that the transience of the effect is 485 shorter than necessary to prevent a harmful effect of the treatment, should there be 486 one. Moreover, the limiting response can be reduced by repeat exposures to the exo-487 dsRNA (Houri-Zeevi & Rechavi 2017 Exposing the eukaryote C. elegans to exo-dsRNA downregulated the production of 501 endo-dsRNAs that are necessary for the inheritance of endo-dsRNA effects (Houri-502
Ze'evi et al. 2016). This effect was not specific to the sequence of the genes 503 controlled by particular endo-dsRNA, but to production of proteins necessary for 504 intergenerational transmission of RNAi caused by endo-dsRNAs. 505
A critical feature of this observation is that any attempt to determine the longevity 506 of exo-dsRNA-mediated RNAi must define how often an organism will be exposed to 507 exo-dsRNA. This is because the "'transgenerational timer' is being reset by initiation 508 of new RNAi responses, and therefore 'second triggers' extend the inheritance of 509 ancestral silencing" (Houri-Ze'evi et al. 2016). Exposure frequencies will determine 510 the duration of the effect both in time and number of generations. 511
512
Conclusion
514
The EPA Decision defines the use of dsRNA applied externally to eukaryotes as out 515 of scope of their legislation. The Decision has important implications because all 516 native and endogenous eukaryotes, even those yet to be discovered, as well as those 517 described as exotics, with the exception of organisms banned by biosecurity laws, 518 come under the jurisdiction of the HSNO Act. 519 A significant concern is that the Decision did not consider the in vitro techniques 520 that could be used either to create, isolate or amplify the dsRNA. The Committee: 521
• put no constraints on the size of the dsRNA molecules. 522
• constrained treatment to organisms that are not excluded by the 523 Biosecurity Act, but did not constrain the source of the dsRNA to be used. 524
• removed any obligation to notify the use of in vitro conversion or 525 synthesis of RNA genomes into dsRNA molecules. 526
• The EPA was certain that exo-dsRNA molecules could not be inherited by 531 eukaryotes and this was the primary rationale for the determination that 532 eukaryotes treated with them were not new or genetically modified organisms for 533 the purposes of the HSNO Act. Prohibiting inheritance were various biological 534 barriers ( Fig. 1) : 535
• exo-dsRNA does not mix with material in the nucleus of the cell. This, 536
however, was shown to be false. Moreover, the EPA failed to account for 537 replicating RNA elements in the cytoplasm of some eukaryotes, and the 538 literature on RNA-RNA recombination. 539
• exo-siRNA is not reverse transcribed. This was shown to be plausible for 540 some dsRNA molecules but demonstrably false for others. 541
• exo-dsRNA is not inheritable because it does not modify the DNA genome. 542
This was shown to be false. First, exo-dsRNA may replicate independently of 543 the DNA genome using RdRP-based amplification, as can other RNA-based 544 elements in eukaryotes that are clearly genetic material. Second, exo-dsRNAs 545 can modify DNA in chromosomes in some cell types or species. Modifications 546 include heritable methylation of nucleotides and histones, DNA deletions and 547 rearrangements, and changes in chromosome copy number. 548
In contrast to the EPA, the industry developing dsRNA treatments for broad scale 549 environmental applications is convinced that the treatments result in heritable 550 changes. For example, an exo-dsRNA treatment was used to effect a color change in 551 flowers of petunia plants that produced progeny that retained the modified trait. 552
Those progeny were used to illustrate the multi-generational claim of ownership 553 made by the patent holder (see paragraph 0173 of Ref. Huang et al. 2018) . 554
Terminology 555
The common understandings of terms not already defined in the HSNO Act served in 556 this instance to reinforce the conclusion that dsRNA did not modify genes or other 557 genetic material (EPA 2018b Likewise, EPA could have reduced compliance costs for those using exo-dsRNA in 616 contained facilities by limiting the approval to synthetically produced and short 617 dsRNA molecules, as requested in the original application, prohibiting dsRNA 618 derived from pathogens such as RNA viruses. Work using dsRNA derived from 619 viruses would then require additional risk assessment. 620
The EPA decision was based on hypothetical barriers to inheritance that are not 621 present in all eukaryotes. Furthermore, it makes possible the use of in vitro 622 techniques that until recently were confined to the laboratory, making it possible to 623 evaluate resulting genetically modified organisms before release. The topical dsRNA 624 and other similar technologies intended to be used in the open air would instead 625 allow the techniques of genetic engineering to be applied in the environment with 626 no potential to evaluate the resulting products before release. In parallel with the 627 use of "e" as a prefix for the adjective environment/al, I call this and other 628 techniques of this type eGE, for environmental genetic engineering. 629
It is important to emphasize that RNA effects are still rapidly being described even 630 in model research organisms. "Among some animal groups [in New Zealand], new 631 species are being discovered faster than scientists can cope with them" (Manatū 632
Taonga Ministry for Culture and Heritage) much less test them for dsRNA responses. 633
The clear statements that there is likely to be much more to discover about dsRNA 634 effects as more species are studied, statements made in the references used to 635 develop advice from staff (EPA 2018b), were not mentioned in the advice provided 636 to the Committee. The narrow treatment by EPA of how dsRNA could modify genes 637 or genetic material is surprising given the nation's pride in its native biodiversity. 638
In the future, it might be determined that some or all uses of externally applied 639 dsRNA create no unmanageable risks to human health, the environment, or to 640 society. This would be a welcome finding because there is potential for dsRNA-641 based products to be at least short-term remedies for some problems. Coming to 642 this position should be an evidence-based and precautionary process. Only that kind 643 of process has the ability to build trust in responsible providers of biotechnology 644 and agencies that serve to protect the public's interest in the environment. Taking 
